

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 to 7. (canceled)

Claim 8. (currently amended) A method of treating ~~and/or preventing~~ a disease of a posterior segment of an eye ~~comprising~~ consisting essentially of administering subconjunctivally to a patient an effective amount for treatment of an injection comprising fine particles containing a drug and enabling the concentration of the drug in a retina-choroid to be sustained, wherein the disease of the posterior segment of the eye is uvetis, cytomegalovirus retinitis, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy[[,]] or retinal detachment[[,]] ~~pigmentary retinal degeneration[[,]] central retinal vein occlusion or central retinal artery occlusion~~ , and a particle diameter of the fine particles is 50 nm to 150  $\mu$ m.

Claim 9. (canceled)

Claim 10. (currently amended) The method of treating ~~and/or preventing~~ the disease of the posterior segment of the eye as claimed in claim 8, wherein the fine particles are made of a biodegradable or biosoluble polymer.

Claim 11. (canceled)

Claim 12. (currently amended) The method of treating ~~and/or preventing~~ the disease of the posterior segment of the eye as claimed in claim 8, wherein the drug is ~~an anti[[,]]inflammatory drug[[,]] an immunosuppressor[[,]] an antiviral[[,]] an anticancer drug[[,]] an angiogenesis inhibitor[[,]] an antithrombotic agent[[,]] an optic neural protectant[[,]] an antimicrobial or an antifungal agent~~ a betamethasone, dexamethasone, triamcinolone or prednisolone.

Claims 13 to 17. (canceled)